Navigation Links
Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results
Date:3/9/2010

e weight than patients on placebo, and they also achieved substantial improvements in glycemic control.  Specifically, Contrave patients showed a 0.6% reduction in hemoglobin A1c (HbA1c) from baseline, compared to a 0.1% reduction in placebo.
  • Key secondary endpoints met across the entire COR Phase 3 program included significant improvements in markers of cardiometabolic risk such as waist circumference, HDL cholesterol and triglycerides.  Additional analyses indicate that Contrave patients experienced an increased ability to control their eating compared to placebo.
  • Contrave was generally well tolerated by patients across the COR Phase 3 program. The most frequently observed treatment-emergent adverse events were nausea, constipation and headache. Nausea was the leading adverse event resulting in discontinuation; however, for the majority of patients experiencing nausea, it was mild to moderate, transient and manageable.

  • The results from the successfully completed COR program of more than 4,500 patients exceed the FDA categorical efficacy benchmark for clinically significant weight loss, supporting the Company's plan to file a New Drug Application with the FDA by the end of April

    Empatic

    In September, Orexigen announced the data from the P
    '/>"/>

    SOURCE Orexigen Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
    2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
    3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
    4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
    5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
    6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
    7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
    8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
    9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
    10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... , Sept. 18, 2014  KIYATEC announced today ... Small Business Innovation Research (SBIR) Phase II Contract ... the 27 institutes and centers that comprise the ... of the two year award, KIYATEC will expand ... issues at the forefront of cancer therapy strategies: ...
    (Date:9/18/2014)... LONDON , September 18, 2014 ... their audience, has updated the incredibly successful Serialisation Countdown ... The interactive PDF, available at pharmaserialisation.com shows ... in which they will be coming into force. ... no longer a matter of "if", but "when" they ...
    (Date:9/18/2014)... ARBOR, Mich. , Sept. 18, 2014  A ... Research will allow the University of Michigan to establish ... The Glenn Center for Aging Research at ... evidence that drugs can slow the effects of aging ... unlock mechanisms of aging that can help develop medications ...
    Breaking Medicine Technology:National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3
    (Date:9/18/2014)... living in disadvantaged neighborhoods have worse musculoskeletal pain ... motor vehicle collision than individuals from higher socioeconomic ... such as age, sex, income, education, and employment ... multi-site research study led by Samuel McLean, MD, ... at the University of North Carolina School of ...
    (Date:9/18/2014)... September 18, 2014 It is almost time ... or walk for healthier and happier kids. The South ... in the 4th Annual Miami Children’s Hospital 5K Run/Walk. ... http://www.hyundaihopeonwheels.org , The 5K will take place on ... be outside of Coral Gables City Hall located at 405 ...
    (Date:9/18/2014)... Good Neighbor Pharmacy, a national independent ... Pharmacy University, an online central resource for network ... empower pharmacy owners and their staff in today’s ... evolve, Good Neighbor Pharmacy is a partner to ... to help their businesses thrive,” said Scott Robinson, ...
    (Date:9/18/2014)... parents eat more vegetables and drink less sugar, according ... Columbia. But it,s still not enough, the study goes ... when it comes to eating healthier at school , ... of socioeconomic status, may inform a child,s diet. , ... some post-secondary education were 85 per cent more likely ...
    (Date:9/18/2014)... Relias Learning, the leader in SaaS-based training and ... announced it has been named to the Inc. 5000 list ... , In the three-year period from 2010 to 2013, Relias ... on the Inc. 5000 list to 1,025 from the company’s ... we serve continue to grow, and the need for quality ...
    Breaking Medicine News(10 mins):Health News:Living in a disadvantaged neighborhood worsens musculoskeletal pain outcomes after trauma 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Good Neighbor Pharmacy University Keeps Pharmacists Ahead of the Curve 2Health News:Kids eat better if their parents went to college 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2
    ... (Nov. 3, 2011) Because the incidence of malignant ... the U.S., researchers at Moffitt Cancer Center in Tampa, ... Carolina University and the University of Arizona are working ... malignant melanoma diagnosis and therapy. A tool of great ...
    ... Reinberg HealthDay Reporter , WEDNESDAY, Nov. 2 ... therapy prolongs survival among men whose cancer has spread ... These men have what is called high-risk, or locally ... to 25 percent fall into this category. In the ...
    ... 3 (HealthDay News) -- The first artificial heart valve ... approved by the U.S. Food and Drug Administration. ... an aortic heart valve damaged by senile aortic valve ... deposits that cause the valve to narrow. One ...
    ... Severe early childhood caries can destroy most of a ... populations, including American Indians and Alaskan natives. Although the ... early childhood caries has been known for almost a ... are responsible for the disease has remained elusive. ...
    ... (HealthDay News) -- Allergy shots are time-tested treatments ... relief to allergy sufferers within weeks instead of months, ... currently given under the skin (subcutaneously), new methods of ... week,s annual scientific meeting of the American College of ...
    ... , WEDNESDAY, Nov. 2 (HealthDay News) -- A compound currently ... hemophilia patients also seems to be effective in preventing bleeds ... in the Nov. 3 edition of the New England ... last long, the results do raise the possibility that, over ...
    Cached Medicine News:Health News:Researchers help in search for new ways to image, therapeutically target melanoma 2Health News:Radiation Plus Hormone Therapy Extends Life in High-Risk Prostate Cancer 2Health News:Radiation Plus Hormone Therapy Extends Life in High-Risk Prostate Cancer 3Health News:FDA OKs Heart Valve That Does Not Require Open-Heart Surgery 2Health News:FDA OKs Heart Valve That Does Not Require Open-Heart Surgery 3Health News:NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria 2Health News:NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria 3Health News:Improved Allergy Shots Might Be on Horizon 2Health News:Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia 2Health News:Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia 3
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: